Skip to main content
Premium Trial:

Request an Annual Quote

NINDS Awards Coriell Institute $7.7M to Support Biorepository

NEW YORK – The US National Institute of Neurological Disorders and Stroke (NINDS) has awarded Coriell Institute for Medical Research $7.7 million for ongoing support of its biorepository.

Under the terms of the five-year contract, Coriell will continue to support the NINDS Human Genetics Research Center. Camden, New Jersey-based Coriell has been the contractor for the NINDS center since its establishment in 2002.

NINDS' biorepository includes samples from subjects with various diseases, including cerebrovascular disease, dystonia, epilepsy, motor neuron disease, parkinsonism, and Tourette syndrome. It also collects demographic, clinical, and other genetic data, which it makes available to researchers globally.

According to Coriell, the new money will support sample processing as well as storage and distribution at the center, in addition to the expansion of resource sub-collections, such as those focused on cerebrovascular disease and dystonia.

The contract will also support work to link samples to genomic data stored in dbGAP, the database of National Institutes of Health Genotypes and Phenotypes.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.